Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F FTC-146 PET/CT in Newly Diagnosed Osteosarcoma
NCT04365660Phase 2Terminated
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]-FTC-146 in osteosarcoma (OS). Primary endpoint: Detection of Tumor Necrosis Post-chemotherapy at 12 weeks. Started Jan 2021; status: terminated.
02
Drugs
[18F]-FTC-146
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04365660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365660.